Levetiracetam Solution
Product Images NDC 0904-7265

8 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0904-7265). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam 1)

Chemical Structure (Levetiracetam 1)
Chemical structure of levetiracetam showing its molecular arrangement with a pyrrolidone ring, an ethyl substituent, and an amide group.*
FDA Label Image

Figure 1 (Levetiracetam 2)

Figure 1 (Levetiracetam 2)
A bar graph showing the percentage of patients responding to different treatments: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The graph compares efficacy across these groups with patient numbers indicated for each treatment.*
FDA Label Image

Figure 2 (Levetiracetam 3)

Figure 2 (Levetiracetam 3)
A vertical bar graph comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis shows the percentage of patients from 0% to 45%, with bars indicating 6.3% for Placebo (N=111), 20.8% for Levetiracetam 1000 mg/day (N=106), and 35.2% for Levetiracetam 2000 mg/day (N=105).*
FDA Label Image

Figure 3 (Levetiracetam 4)

Figure 3 (Levetiracetam 4)
Bar chart comparing the percentage of patients in two groups: one receiving Placebo (N=104) with 14.4%, and the other receiving Levetiracetam 3000 mg/day (N=180) with 39.4%. The vertical axis represents the percentage of patients.*
FDA Label Image

Figure 4 (Levetiracetam 5)

Figure 4 (Levetiracetam 5)
A bar chart comparing the percentage of patients in two groups: Placebo (19.6% of 97 patients) and Levetiracetam (44.6% of 101 patients). The vertical axis represents the percentage of patients from 0% to 45%, with Levetiracetam showing a higher patient percentage than Placebo.*
FDA Label Image

Figure 5 (Levetiracetam 6)

Figure 5 (Levetiracetam 6)
A bar chart comparing the percentage of patients between a placebo group and a Levetiracetam group. The placebo group (n=51) shows 19.6% of patients, while the Levetiracetam group (n=58) shows 43.1% of patients with a statistically significant difference marked.*
FDA Label Image

Figure 6 (Levetiracetam 7)

Figure 6 (Levetiracetam 7)
A bar chart comparing the percentage of patients between two groups: Placebo (45.2%) and Levetiracetam (72.2%). The x-axis labels the groups, and the y-axis represents the percentage of patients from 0% to 100%. Levetiracetam group shows a higher percentage than the placebo group.*
FDA Label Image

Lidding On 5 mL (Levetiracetam 8)

Lidding On 5 mL (Levetiracetam 8)
Levetiracetam Oral Solution USP 500 mg/5 mL label from Major Pharmaceuticals showing a single-dose delivery of 5 mL. The label includes NDC 0904-7265-41, instructions for institutional use only, and a note that the package is not child-resistant. The label is predominantly white with purple and blue accents and displays a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.